# **Product** Data Sheet

# AZD5597

Cat. No.: HY-50914 CAS No.: 924641-59-8 Molecular Formula: C<sub>23</sub>H<sub>28</sub>FN<sub>7</sub>O Molecular Weight: 437.51 Target: CDK

Pathway: Cell Cycle/DNA Damage Storage: 4°C, protect from light

\* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

### **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (228.57 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.2857 mL	11.4283 mL	22.8566 mL
	5 mM	0.4571 mL	2.2857 mL	4.5713 mL
	10 mM	0.2286 mL	1.1428 mL	2.2857 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.71 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.71 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.71 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	AZD5597 is an inhibitor of CDK with an IC <sub>50</sub> of 2 nM. AZD5597 has potent anti-proliferative effects against a range of cancer cell lines <sup>[1]</sup> .
IC <sub>50</sub> & Target	IC50: 2 nM (CDK2), 2 nM (CDK1), 39 nM (LoVo) <sup>[1]</sup>

#### **REFERENCES**

1]. Jones CD, et al.The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing. Bioorg Med Chem Lett. 2008 Dec 5;18(24):6369-73.						
	Caution: Product has no	t been fully validated for med	dical applications. For research u	se only.		
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemExpre			
	Address: 1 [	Deer Park Dr, Suite Q, Monmo	uth Junction, NJ 08852, USA			

Page 2 of 2 www.MedChemExpress.com